Search research articles
Contact Us
Filters
Showing results (151-160 of 173) with videos related to
Page
of 18
Sort By:
The New England Journal of Medicine
|
July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Ignace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Ebiomedicine
|
October 12, 2024
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma
Loic Verlingue, Antoine Italiano, Hans Prenen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 21, 2026
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes
Christian Marth, Domenica Lorusso, Mariusz Bidziński, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 2, 2026
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy
Matthew A Powell, Sharad Ghamande, Lars C Hanker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
The Lancet. Oncology
|
July 31, 2025
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025
Nicole Concin, Xavier Matias-Guiu, David Cibula, et al.
Lancet (London, England)
|
September 17, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Lancet (London, England)
|
March 23, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Gynecologic Oncology
|
April 18, 2026
Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study
Els Van Nieuwenhuysen, Ignace Vergote, Leslie M Randall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 11, 2025
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 173) with videos related to
Sort By:
Page
of 18
The New England Journal of Medicine
|
July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Ignace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Ebiomedicine
|
October 12, 2024
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma
Loic Verlingue, Antoine Italiano, Hans Prenen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 21, 2026
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes
Christian Marth, Domenica Lorusso, Mariusz Bidziński, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 2, 2026
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy
Matthew A Powell, Sharad Ghamande, Lars C Hanker, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
The Lancet. Oncology
|
July 31, 2025
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025
Nicole Concin, Xavier Matias-Guiu, David Cibula, et al.
Lancet (London, England)
|
September 17, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Lancet (London, England)
|
March 23, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Domenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Gynecologic Oncology
|
April 18, 2026
Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study
Els Van Nieuwenhuysen, Ignace Vergote, Leslie M Randall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 11, 2025
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, et al.
Page
of 18